Conferences - Results from #7380

ASCO 2018: Leveraging Social Media to Advance Cancer Research: Challenges and Opportunities June 6, 2018

ASCO 2018: KEYNOTE-199: Pembrolizumab for docetaxel-refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC) June 6, 2018

ASCO 2018: KEYNOTE-564: A Phase 3, Randomized, Double Blind, Trial of Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma June 6, 2018

ASCO 2018: Nivolumab for Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Institution Experience June 6, 2018

ASCO 2018: Effectiveness and Safety of Pazopanib and Everolimus in a Changing Treatment Landscape: Interim Results of the Non-Interventional Study PAZOREAL June 6, 2018

ASCO 2018: Optimization of PD-L1 Algorithm for Predicting OS in Patients with Urothelial Cancer Treated with Durvalumab June 6, 2018

ASCO 2018: Association of Metastasis-Free Survival and Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer June 6, 2018

ASCO 2018: Precision Active Surveillance: Can Genomic Data Inform Management? June 6, 2018

ASCO 2018: Judicious Use of Therapeutics and Imaging in Early-Stage Prostate Cancer June 6, 2018

ASCO 2018: A Randomized Study of Finite Abiraterone Acetate Plus Leuprolide Versus Leuprolide in Biochemically Recurrent Non-Metastatic Hormone Naïve Prostate Cancer June 6, 2018

ASCO 2018: Prospective, Multinational, Observational Study of Real-World Treatment Outcomes with Pazopanib in Patients with Advanced or Metastatic Renal Cell Carcinoma (Principal Study) June 5, 2018

ASCO 2018: SPCG-13: A Randomized Phase III Trial Between Adjuvant Docetaxel and Surveillance after Radical Radiotherapy for Intermediate and High-Risk Prostate Cancer June 5, 2018

ASCO 2018: Tailoring of Chemotherapy to Fit Patients with Metastatic Urothelial Cancer June 5, 2018

ASCO 2018: Accuracy of 68Ga-PSMA11 PET/CT on Recurrent Prostate Cancer: Preliminary Results from a Phase 2/3 Prospective Trial June 5, 2018

ASCO 2018: The PROPHECY Trial: Multicenter Prospective Trial of Circulating Tumor Cell AR-V7 Detection in Men with mCRPC Receiving Abiraterone or Enzalutamide June 5, 2018

ASCO 2018: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Randomized Phase II Trial June 5, 2018

ASCO 2018: Overall Survival Between African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer June 5, 2018

ASCO 2018: Targeted Therapies in Advanced Urothelial Cancer June 5, 2018

ASCO 2018: Results for 2nd-line Therapy: A Cross-over Trial, Abiraterone + Prednisone vs Enzalutamide for Patients Metastatic Castration-Resistant Prostate Cancer June 5, 2018

ASCO 2018: Immunotherapy-Based Approaches for Advanced Urothelial Cancer June 5, 2018

Page 370 of 590